Institute: Sydney Children's Hospital
Recipient: Associate Professor David Ziegler
Funding: $278,282 July 2019 to June 2022
DIPG is the most agressive cancer to affect children, with no known curative therapies. 
Diffuse Intrinsic Pontine Gliomas (DIPG) are the most aggressive of all childhood cancers. Due to their location within the brainstem, they cannot be removed surgically, they do not respond to chemotherapy, and radiotherapy is palliative only.
 
Innovative treatment approaches are urgently needed.
 
The Ziegler laboratory has found that a new class of drugs called Polo-like kinase 1 (PLK1) inhibitors are highly potent against the first DIPG cells ever grown in the laboratory. Further, that this new drug works well in synergy with an existing medication prescribed to treat other cancers.
 
This important discovery will be used to develop the optimal combination therapy at the bench with a view to fast tracking findings to the bedside to directly benefit children with DIPG. 

This project recieved further support through Cancer Australia's Priority-driven Collaborative Cancer Research Scheme.
 
Science is the solution for kids with cancer
The only way to improve outcomes for children diagnosed with cancer is through advances in medical research. Every day and every donation takes us closer to a cure.
Select your donation details
Please enter the amount you would like to donate

The Kids' Cancer Project is an ACNC Registered Charity 
ABN 13 061 138 181 | CFN 10581